Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

February 28, 2029

Study Completion Date

November 30, 2030

Conditions
Advanced MelanomaMetastatic Melanoma
Interventions
BIOLOGICAL

Cytokine-induced memory-like natural killer cells

Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).

BIOLOGICAL

Relatilmab

Standard of care

BIOLOGICAL

Nivolumab

Standard of care

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

Melanoma Research Alliance

OTHER

collaborator

Rising Tide Foundation

OTHER

lead

Washington University School of Medicine

OTHER